| P50 | author | Arie Perry | Q37837647 |
| | Vijay Ramaswamy | Q43153342 |
| | Charles G Eberhart | Q87148391 |
| | Paul A Northcott | Q91826566 |
| P2093 | author name string | Michael D Taylor | |
| | James M Olson | |
| | Sameer Agnihotri | |
| | Sidney E Croul | |
| | Adrian M Dubuc | |
| | Donya Aref | |
| | Connor J Moffatt | |
| P2860 | cites work | Molecular subgroups of medulloblastoma: the current consensus | Q24615271 |
| | Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 |
| | Subtypes of medulloblastoma have distinct developmental origins | Q28300616 |
| | Cerebellum development and medulloblastoma | Q28304753 |
| | Development and cancer of the cerebellum | Q28305235 |
| | Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation | Q28505942 |
| | DNA array analysis of the developing rat cerebellum: transforming growth factor-beta2 inhibits constitutively activated NF-kappaB in granule neurons | Q28575059 |
| | The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 |
| | TM4 microarray software suite | Q29618829 |
| | Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features | Q33366431 |
| | Central nervous system neuronal migration | Q33593457 |
| | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 |
| | Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features | Q34866372 |
| | Smad2 protein disruption in the central nervous system leads to aberrant cerebellar development and early postnatal ataxia in mice | Q34998146 |
| | Clonal selection drives genetic divergence of metastatic medulloblastoma | Q35784926 |
| | Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples | Q35837393 |
| | MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway | Q35907425 |
| | Morphing into cancer: the role of developmental signaling pathways in brain tumor formation | Q36205991 |
| | c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer | Q36294128 |
| | Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups | Q36460209 |
| | Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development | Q36509989 |
| | Transforming growth factor-beta in cancer and metastasis | Q36585129 |
| | Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons | Q36735270 |
| | Medulloblastoma comprises four distinct molecular variants | Q36920479 |
| | The origins of medulloblastoma subtypes | Q37014819 |
| | Noncanonical TGF-β signaling during mammary tumorigenesis | Q37044600 |
| | Role of TGF-β and the tumor microenvironment during mammary tumorigenesis | Q37044604 |
| | The TGF-beta paradox in human cancer: an update | Q37261631 |
| | Molecular diagnostics of CNS embryonal tumors | Q37794829 |
| | Medulloblastomas: update on a heterogeneous disease | Q37926454 |
| | Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. | Q39469388 |
| | MicroRNA-21 suppression impedes medulloblastoma cell migration | Q39503647 |
| | Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma | Q39593013 |
| | FOXG1 dysregulation is a frequent event in medulloblastoma | Q40128459 |
| | Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence | Q41980817 |
| | Enhanced neurogenesis from neural progenitor cells with G1/S-phase cell cycle arrest is mediated by transforming growth factor beta1. | Q46376497 |
| | Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression | Q46507354 |
| | Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. | Q46939297 |
| | Smad2/3 activities are required for induction and patterning of the neuroectoderm in zebrafish | Q47074019 |
| | TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis | Q48125390 |
| | Transient production of TGF-beta 2 by postnatal cerebellar neurons and its effect on neuroblast proliferation | Q48129225 |
| | Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification | Q48194323 |
| | BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect | Q48249566 |
| | Transforming growth factor-beta 2 both stimulates and inhibits neurogenesis of rat cerebellar granule cells in culture | Q48888000 |
| | TGF-beta2 neutralization inhibits proliferation and activates apoptosis of cerebellar granule cell precurors in the developing cerebellum | Q48945809 |
| | The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. | Q53492300 |
| | Adult medulloblastoma comprises three major molecular variants. | Q55463035 |
| P433 | issue | 2 | |
| P921 | main subject | medulloblastoma | Q1333608 |
| P304 | page(s) | 178-191 | |
| P577 | publication date | 2012-10-11 | |
| P1433 | published in | Brain Pathology | Q4955776 |
| P1476 | title | Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development | |
| P478 | volume | 23 | |